Sol-Gel Technologies Ltd

-0.33 (-2.94%)
Products, Regulatory, Other Pre-Announcement

Sol-Gel Announces Pipeline Update And Future Development Plans

Published: 06/28/2021 09:18 GMT
Sol-Gel Technologies Ltd (SLGL) - Announces Pipeline Update and Future Development Plans.
Sol Gel Technologies-investigational Sgt-510 Was Found to Be More Effective Than Roflumilast Cream, 0.3%, in a Human Xenograft Psoriasis Animal Model.
Sol-gel Filed a Provisional Patent Application for Its Novel and Non-obvious Formulation of Sgt-510.
Proof-of-concept Study for Sgt-210 (erlotinib Gel) in Palmoplantar Keratoderma Patients Completed, Indicated Possible Modest Improvement.
By 2022 End, Co Expects to Have Data Against a Formulation of Roflumilast Cream, Expects to Initiate Phase 2 Work Thereafter.